股价表现 - 公司股价在周五交易中创下52周新高 盘中最高触及20[1][1]15美元 最终收盘上涨16[1][1]29%至18[1][1]99美元 [1] 第三季度财务业绩 - 第三季度净亏损同比收窄28%至2850万美元 去年同期为3960万美元 [2] - 毛利润同比增长33%至1[2][2]37亿美元 去年同期为1[2][2]027亿美元 [2] 管理层评论与未来展望 - 公司董事长兼首席执行官表示 公司正在实现可持续的、盈利的收入增长并产生现金流 并处于独特的领先地位 [3] - 公司预计2025年全年总收入将同比增长24%至7[3][3]6亿美元 高于此前给出的7[3][3]42亿美元的预期 [3] 公司业务 - 公司是一家医疗设备公司 通过其全资子公司致力于通过临床差异化彻底改变脊柱外科手术方法 [4]

根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息 文档内容仅为一条技术性提示 要求用户启用浏览器中的Javascript和cookies 并可能涉及禁用广告拦截器以继续操作 [1]

文章核心观点 - 截至2025年10月31日，医疗保健板块中有两只股票可能向将动量作为关键交易标准的投资者发出警示信号 [1] - 这两只股票因近期财报表现强劲而股价上涨，但其相对强弱指数（RSI）已进入超买区间，暗示短期可能存在回调风险 [2][7] 相对强弱指数（RSI）指标分析 - RSI是动量指标，通过比较股票在上涨日和下跌日的强度来评估其短期表现 [2] - 根据Benzinga Pro，当RSI高于70时，资产通常被视为超买 [2] Alphatec Holdings Inc (ATEC) 分析 - 公司于10月30日公布了超预期的第三季度财务业绩，并上调了2025财年销售指引，该指引高于市场预估 [7] - 公司股价在过去一个月上涨约12%，52周高点为17.14美元 [7] - 该股RSI值为82.5，处于超买区间 [7] - 公司股票在周四下跌1%，报收于16.33美元 [7] - 该股动量评分为91.00 [7] Travere Therapeutics Inc (TVTX) 分析 - 公司于10月30日公布了超预期的第三季度销售业绩 [7] - 公司股价在过去一个月上涨约24%，52周高点为30.97美元 [7] - 该股RSI值为80.9，处于超买区间 [7] - 公司股票在周四下跌1.1%，报收于29.65美元 [7]

Alphatec Holdings, Inc. (ATEC) shares jumped more than 22% in pre-market trading on Friday after the medical company reported improved third-quarter results and raised its full-year outlook.The company posted a net loss of $28.58 million, or $0.19 per share, narrowing from $39.62 million, or $0.28 per share loss, in the same period last year.Excluding one-time items, Alphatec reported adjusted income of $4.09 million, or $0.03 per share, compared with a loss of $10.64 million, or $0.07 per share, a year ag ...

季度业绩表现 - 公司第三季度每股收益为0.03美元，远超市场预期的每股亏损0.03美元，相比去年同期的每股亏损0.28美元实现大幅改善 [1] - 当季营收达到1.965亿美元，超出市场预期7.64%，较去年同期的1.5072亿美元显著增长 [3] - 本季度盈利超出预期幅度达200.00%，上一季度盈利超出预期幅度为133.33% [2] 历史业绩与市场表现 - 在过去四个季度中，公司有两次超过市场每股收益预期，四次超过市场营收预期 [2][3] - 公司股价年初至今累计上涨约79.6%，表现远超同期标普500指数17.2%的涨幅 [4] 未来业绩展望 - 市场对公司下一季度的共识预期为每股收益0.04美元，营收2.0474亿美元 [8] - 对本财年的共识预期为每股亏损0.02美元，营收7.4202亿美元 [8] - 业绩公布前，公司盈利预期修正趋势好坏参半，目前Zacks评级为第3级（持有） [7] 行业比较与前景 - 公司所属的医疗器械行业在Zacks行业排名中位列前39%，研究表明排名前50%的行业表现优于后50%的行业，优势超过2比1 [9] - 同业公司Tactile Systems Technology预计第三季度每股收益为0.16美元，同比下滑33.3%，预计营收为7938万美元，同比增长8.6% [10][11]

Alphatec (NasdaqGS:ATEC) Q3 2025 Earnings Call October 30, 2025 04:30 PM ET Speaker8Good afternoon, everyone, and welcome to the webcast of Alphatec's third-quarter financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC. During this c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52024 ALPHATEC HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-2463898 ...

Q3 2025 FINANCIAL RESULTS FORWARD-LOOKING STATEMENTS 3 Q3 2025 FINANCIAL HIGHLIGHTS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors tha ...

Exhibit 99.1 ATEC Reports Third Quarter 2025 Financial Results And Raises Full-Year Guidance CARLSBAD, Calif., October 30, 2025 – Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2025, and recent corporate highlights. Third Quarter 2025 Financial Results | | Quarter Ended September 30, 2025 | | --- | --- | | Total revenue | $197 million | | ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying ALB stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...